1 / 18

I.V.I.G

I.V.I.G . BY: MOHAMMED ALSAIDAN. IVIG. IVIg is a blood product derivative manufactured from the sterilized, purified human plasma of between 1000 to 20,000 donors per batch . The final IVIg preparation is primarily composed of IgG , with trace amounts of IgA, IgM and albumin

cindy
Download Presentation

I.V.I.G

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. I.V.I.G BY: MOHAMMED ALSAIDAN

  2. IVIG • IVIg is a blood product derivativemanufactured from the sterilized, purified human plasma of between 1000 to 20,000 donors per batch. • The final IVIg preparation is primarily composed of IgG, with trace amounts of IgA, IgM and albumin • half-life of IVIg ranges from 3-5 weeks • Crosses the placenta, and may be excreted in milk • Distributed : 60% intravascular , 40 % extravascular

  3. MOA • Functional blockade of the Fc receptors • Neutralize complement , and block complement activation in early stage • Anti-idiopathic antibodies can neutralize pathogenic antibodies • Interfere with T-cell activation

  4. MOA • Interfere with cellular migration • Increase glucocorticoid receptor sensitivity • In toxic epidermal necrolysis, IVIg blocks Fas (CD95) mediated keratinocyte death by inhibiting Fas – Fas ligand interactions

  5. Indications • The efficacy of IVIg is best documented in patients with: • graft-versus-host disease • Kawasaki’s disease • dermatomyositis • Autuimmune bullous dermatosis: • pemphigus vulgaris • pemphigus foliaceus • bullous pemphigoid • herpes gestationis • epidermolysisbullosaacquisita (EBA) • TEN/ SJS

  6. Indications • Other indications: • Atopic dermatitis • psoriasis • scleroderma • Pyodermagangrenosum • Chronic autoimmune urticaia

  7. When to use IVIG for bullous dis. 1)Progressive, uncontrolled,orrapid debilitating disease failure of conventional therapy 2) significant adverse effects from conventional therapy 3) contraindications, relative or absolute, to the use of high-dose long-term systemic therapy *The patient age and pregnancy are not contraindications to the use of IVIG

  8. Before starting IVIG • Vital signs • Weight to monitor for overload • Auscultate lungs and heart • Labs: • CBC • LFT • Renal profile • Immunoglobulin levels • RF and in patients at an increased risk of acute renal failure • For medicolegalreasons: HBV, HCV and HIV is advisable

  9. Pre medication • To minimize the risk of infusion-related side effects, such as headaches, myalgias and rigors. • Analgesics (i.e., acetaminophen) • Antihistamines (i.e., diphenhydramine) • NSAID (i.e., celecoxib) • low-dose intravenous corticosteroids may be of benefit to a subset of individuals

  10. Dosage • The most common dosage in dermatology is 2 g/kg/cycle divided into 3 equal doses in 3 consecutive days • Or 400mg/kg daily for 5 days • Infusion: Slowly over 4 to 4 ½ hours • Given monthly , but can be given every 2 weeks in very aggressive disease • Tapering : keep the same dose with increasing the interval between infusions by 2 weeks (4,6,8,10,12,14,16) then D/C

  11. Dosage • Careful monitoring for 1st infusion or different preparation • All patients must be well hydrated prior to the infusion . • When all these measures fail to correct or prevent the adverse reactions it could be useful to change to a different preparation of IVIG

  12. Anaphylaxis reaction • More frequently with antibody deficiency , mainly in IgA deficiency with antibody against IgA • Slow infusion seems to lower the risks • Resolve with temporary interruption of the infusion or a slowing of its rate of administration • Can be prevented by giving , paracetamol or anti-histamines before the treatment and/or hydrocortisone during it.

  13. Thromboembolic events • Secondary to increased viscosity , leading to cerebral or myocardial infarction • RISK FACTORS: • higher doses or rapid infusion • elderly patients • patients with previous cerebral or cardiac ischaemia • overweight patients • Those who are markedly hypovolaemic and immobilised

  14. Aseptic menengitis • observed in patients with neurological and neuromuscular diseases treated with high doses of IVIG. • The symptoms appear within 6–24 hours of the end of the infusion and disappear without sequelae in 3–5 days

  15. Renal disease • Increases in creatinine or acute renal failure rarely in elderly, diabetic, poorly hydrated patients, with pre-existing renal disease or who are taking nephrotoxic drugs. • These problems are probably related to damage caused to the renal tubules by the saccharose included in various preparations as a stabiliser.

More Related